Momenta Phamaceuticals, Inc. (MNTA) Misses Q3 EPS by 12c
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Financial Fact:
Operating income (loss): -18.18M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Operating income (loss): -18.18M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q3 EPS of $1.18, $0.12 worse than the analyst estimate of $1.30. Revenue for the quarter came in at $87.9 million versus the consensus estimate of $90.92 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
